Description

• General description: This product is provided as delivered and specified by the issuing pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the authority of the issuing pharmacopoeia. For further information and support please go to the website of the issuing pharmacopoeia. Tretinoin is a medication used to treat a variety of skin conditions such as photodamaged skin, acne, etc. It is used as an anti-aging product and also as an oral treatment for leukemia.[1]
• Application: This European Pharmacopoeia reference standard is intended for use only as specifically prescribed in the European Pharmacopoeia.
• Biochem/physiol Actions: all−trans−Retinoic acid (ATRA) is a ligand for both the retinoic acid receptor (RAR) and the retinoid X receptor (RXR). The bound RAR and RXR act as transcription factors that regulate the growth and differentiation of both normal and malignant cells. Cytochromes P450 (CYPs) catalyze the 4-hydroxylation of ATRA. Retinoic acid primes embryonic stem cells to become neurons.
• Packaging: The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
• Other Notes: Sales restrictions may apply.